| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD007114.PUB2 |
| P698 | PubMed publication ID | 22786503 |
| P50 | author | Catey Bunce | Q28039205 |
| P2093 | author name string | Rathie Rajendram | |
| Ana MS Morley | |||
| Richard WJ Lee | |||
| P2860 | cites work | Recent developments in thyroid eye disease | Q24564205 |
| Graves' ophthalmopathy | Q28274196 | ||
| Orbital radiotherapy for thyroid-related orbitopathy | Q28291443 | ||
| Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial | Q30481543 | ||
| The use of orbital radiotherapy for Graves' ophthalmopathy: quantitative review of the evidence | Q33311685 | ||
| Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach | Q33647383 | ||
| Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. | Q34394088 | ||
| Long-term results of irradiation for patients with progressive Graves' ophthalmopathy | Q34430156 | ||
| Does radiotherapy have a role in the management of thyroid orbitopathy? View 1 | Q34500982 | ||
| Does radiotherapy have a role in the management of thyroid orbitopathy? Comment | Q34503706 | ||
| The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. | Q35605719 | ||
| Risk factors for development or deterioration of Graves' ophthalmopathy | Q35975724 | ||
| Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers | Q36568033 | ||
| Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology | Q37033302 | ||
| Immune mechanisms in thyroid eye disease. | Q37254482 | ||
| Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis | Q37505761 | ||
| The Orbital Fibroblast: A Key Player and Target for Therapy in Graves’ Ophthalmopathy | Q37784810 | ||
| A long-term follow-up study after retro-orbital irradiation for Graves' ophthalmopathy | Q38490904 | ||
| Immunosuppressant therapy of thyroid eye disease | Q39568202 | ||
| Mechanisms of the anti-inflammatory activity of low-dose radiation therapy | Q41009007 | ||
| Long-term effects of Graves' ophthalmopathy on health-related quality of life | Q44011939 | ||
| The aftermath of orbital radiotherapy for graves' ophthalmopathy | Q44203609 | ||
| Retinal Microvascular Abnormalities in Patients Treated With External Radiation for Graves Ophthalmopathy | Q44438390 | ||
| High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy | Q44504847 | ||
| Long-term safety of orbital radiotherapy for Graves' ophthalmopathy | Q44547490 | ||
| Orbital irradiation for Graves' ophthalmopathy: Is it safe? A long-term follow-up study | Q45003668 | ||
| Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. | Q45096631 | ||
| Effect of combined intravenous glucocorticoids and orbital radiotherapy in restoring driving competency in patients with Graves' orbitopathy | Q46132685 | ||
| Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. | Q50933902 | ||
| A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. | Q53359335 | ||
| Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. | Q53489903 | ||
| Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy | Q62096682 | ||
| Modification of the Classification of the Eye Changes of Graves' Disease: Recommendations of the Ad Hoc Committee of The American Thyroid Association | Q67020629 | ||
| Supervoltage orbital radiotherapy for Graves' ophthalmopathy | Q67249584 | ||
| Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy | Q69288448 | ||
| Orbital Cobalt Irradiation Combined with Systemic Corticosteroids for Graves' Ophthalmopathy: Comparison with Systemic Corticosteroids Alone* | Q70251349 | ||
| Pathogenesis of Graves' ophthalmopathy | Q70513409 | ||
| Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy | Q72235149 | ||
| Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic | Q72800952 | ||
| Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study | Q73761107 | ||
| Radiation therapy for Graves' ophthalmopathy: trick or treat? | Q74459175 | ||
| A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy | Q74459180 | ||
| Orbital radiotherapy for Graves' ophthalmopathy | Q75236052 | ||
| A questionnaire survey on the management of Graves' orbitopathy in Europe | Q79988590 | ||
| P921 | main subject | adaptive radiation therapy | Q180507 |
| eye disease | Q3041498 | ||
| P577 | publication date | 2012-07-11 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Orbital radiotherapy for adult thyroid eye disease |
| Q36348372 | A review of Cochrane systematic reviews of interventions relevant to orthoptic practice |
| Q37106626 | Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy |
| Q35808258 | Common Immunosuppressive Monotherapy for Graves' Ophthalmopathy: A Meta-Analysis. |
| Q61797316 | Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures |
| Q39159003 | Orbital Decompression for Thyroid Eye Disease |
| Q24202845 | Rituximab for thyroid-associated ophthalmopathy |
| Q35064588 | Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial |
| Q93333216 | Tocilizumab for thyroid eye disease |
| Q94355143 | Tocilizumab for thyroid eye disease |
| Q41665052 | Treatment of Graves' ophthalmopathy with an in-house Phosphorus-32 source: Initial clinical observations |
Search more.